Biogen Netherlands B.V.
SpainAll drugs from this manufacturer
-
It is used to treat multiple sclerosis (MS). It may help reduce the number of relapses and slow down the disabling effects of the disease, although it is not a cure.
Dosage form: solution for injection in pre-filled pen
Active substance Dosage interferon beta-1a 30 µg -
It is used to treat relapsing multiple sclerosis (RMS) in adults aged 18 years or older. It helps to reduce the number of relapses and slow down the disabling effects of the disease, although it is not a cure.
Dosage form: solution for injection in pre-filled pen
Active substance Dosage peginterferon beta-1a 125 µg -
It is used to treat relapsing-remitting multiple sclerosis (RRMS) in adults aged 18 years or older. It helps reduce the number of relapses and slow the progression of the disease, although it is not a cure.
Dosage form: solution for injection in a pre-filled syringe
Active substance Dosage peginterferon beta-1a 125 microgramos/ml -
It is used to treat Relapsing Remitting Multiple Sclerosis (RRMS) in adults aged 18 years or older. It helps to reduce the number of relapses and slow the progression of the disease, although it is not a cure.
Dosage form: solution for injection in a pre-filled syringe
Active substance Dosage peginterferon beta-1a 125 µg -
It is used to treat relapsing multiple sclerosis (RMS) in adults aged 18 years or older. It helps to reduce the number of relapses and slow the progression of the disease, although it is not a cure.
Dosage form: solution for injection in pre-filled pen
Active substance Dosage peginterferon beta-1a 63 µg peginterferon beta-1a 94 µg -
It is used to treat Relapsing Remitting Multiple Sclerosis (RRMS) in adults aged 18 years or older. It helps reduce the number of relapses and slow down the disabling effects of the disease, although it does not cure it.
Dosage form: solution for injection in a pre-filled syringe
Active substance Dosage peginterferon beta-1a 63 µg peginterferon beta-1a 94 µg -
It is used in adults to treat a type of amyotrophic lateral sclerosis (ALS) caused by mutations in the SOD1 gene. It helps reduce the accumulation of a toxic protein to prevent the destruction of motor neurons and may slow the loss of muscle strength.
Dosage form: solution for injection
Active substance Dosage tofersen 100 mg -
It is used to treat adults and adolescents aged 16 and older who suffer from Friedreich's ataxia, a neurodegenerative movement disorder.
Dosage form: capsules, hard
Active substance Dosage omaveloxolona 50 mg -
It is used to treat spinal muscular atrophy (SMA), a genetic disease that causes muscle weakness due to the lack of a protein called SMN.
Dosage form: solution for injection
Active substance Dosage nusinersen 2,40 mg -
It is used to treat relapsing-remitting multiple sclerosis (RRMS) in people aged 13 years and older.
Dosage form: capsules, hard, enteric-coated
Active substance Dosage dimethyl fumarate 120 mg -
It is used to treat relapsing-remitting multiple sclerosis (RRMS) in patients 13 years of age and older. It helps prevent the body's defense system from damaging the brain and spinal cord.
Dosage form: capsules, hard, enteric-coated
Active substance Dosage dimethyl fumarate 240 mg -
It is used to treat multiple sclerosis (MS) in adults. It helps to reduce the number of relapses and to slow the progression of disability caused by this disease.
Dosage form: solution for injection in a pre-filled syringe
Active substance Dosage natalizumab 150 mg/ml -
It is used to treat multiple sclerosis (MS) in adults. It helps to reduce the number of relapses and the progression of disability caused by this disease.
Dosage form: solution for infusion, concentrate
Active substance Dosage natalizumab 20 mg -
It is used to treat relapsing-remitting multiple sclerosis (RRMS) in adults.
Dosage form: capsules, hard, enteric-coated
Active substance Dosage diroximel fumarate 231 mg